These results further support the relevance of TMEM167A function to maintain EGFR signaling in wild-type p53 gliomas and suggest that the antitumor effect of TMEM167A downregulation is independent on the presence of amplifications and/or mutations in the receptor’s gene. This evidence concerns the gene TP53 and glioma.